* A special double-episode of New Insight with Veeral Sheth, MD features a well-rounded conversation on all things ophthalmology with returning guest David Eichenbaum, MD, the director of research for Retina Vitreous Associates of Florida, as well as first-time guest Roger Goldberg, MD, a vitreoretinal surgeon at Bay Area Retina Associates. The trio of retina specialists discuss recent conference news, the anniversary of a landmark agent, and what’s to come in 2024 for the specialty. Episode Highlights: 0:00 https://www.youtube.com/watch?v=F3fQZQOaT38&t=0s Introduction 1:25 https://www.youtube.com/watch?v=F3fQZQOaT38&t=85s Entering 2024 7:34 https://www.youtube.com/watch?v=F3fQZQOaT38&t=454s The importance of treatment efficacy 12:09 https://www.youtube.com/watch?v=F3fQZQOaT38&t=729s Re-engaging GA treatment 15:05 https://www.youtube.com/watch?v=F3fQZQOaT38&t=905s Comparing aflibercept 8 mg and faricimab 23:00 https://www.youtube.com/watch?v=F3fQZQOaT38&t=1380s Real-world data sets 26:30 https://www.youtube.com/watch?v=F3fQZQOaT38&t=1590s What’s to come in 2024 27:45 https://www.youtube.com/watch?v=F3fQZQOaT38&t=1665s Intravitreal gene therapies 31:00 https://www.youtube.com/watch?v=F3fQZQOaT38&t=1860s Port delivery system 36:00 https://www.youtube.com/watch?v=F3fQZQOaT38&t=2160s Wrapping-up Every episode of New Insight is available on HCPLive.com http://HCPLive.com and be sure to subscribe to our channel on Spotify and Apple Podcasts. Please direct any podcast-related inquiries to show producer Connor Iapoce at email@example.com.
* In every episode of New Insight, Veeral Sheth, MD, Director of Clinical Trials at University Retina in Chicago, takes an in-depth look at the biggest news in ophthalmology and the behind the scenes work involved in eye care, with a rotation of guest experts involved in ophthalmic research, development, and clinical care. The latest episode of New Insight features a conversation with Ocuphire Pharma’s CEO on the company’s flagship retinal product and leading a small, but high-powered research team. Episode Highlights: 0:04 Introduction 1:23 History of Ocuphire Pharma 3:50 Leading a small, high-functioning team 6:41 Magrath’s background and journey 11:02 APX3330 for Diabetic Retinopathy 15:20 2024 Plans for Ocuphire 18:53 Addressing unmet needs 20:20 Outro Every episode of New Insight is available on HCPLive.com http://HCPLive.com and be sure to subscribe to our channel on Spotify and Apple Podcasts. Please direct any podcast-related inquiries to show producer Connor Iapoce at firstname.lastname@example.org.
* On the floor at AAO 2023, host Veeral Sheth, MD, and producer Connor Iapoce discuss UBX1325 for patients with diabetic macular edema, based on the 48-week results from the phase 2 BEHOLD study. EPISODE HIGHLIGHTS: 0:30 Introduction 0:48 Background into UBX1325 and BEHOLD 2:49 BEHOLD 48-week results 6:05 Next steps 6:56 Conclusion Please direct any podcast-related inquiries to email@example.com.
* Episode Highlights 0:12 Intro 1:24 Challenges in autoimmune hepatitis 3:30 Patient demographics 4:25 Diagnostic challenges 6:35 What is overlap syndrome? 8:04 Mysteries behind immune dysregulation 9:05 Promising drugs in investigation 10:51 The BAFF receptor target 11:41 Infliximab & rituximab 12:38 An autoimmune hepatitis wishlist 15:29 Outro Autoimmune hepatitis (AIH), a rare liver disease characterized by an unclear driver of inflammation, is historically challenged by limited clinical understanding, a slow development of treatment options in investigation, and a nonetheless concerning prognosis for affected adults and children. While some prospects are in development to aid specialists in adequately identifying risk factors for, diagnosing and treating AIH, education and communication on those developments is vital. In an interview with during the American College of Gastroenterology (ACG 2023) Annual Scientific Meeting in Vancouver, BC this week, Gina Choi, MD, associator clinical professor of medicine and surgery at UCLA Health, discussed the ins and outs of modern autoimmune liver disease research and development. Including the treatment pipeline and current standards for diagnostics, Choi additionally discussed the sociodemographic and pathophysiological traits of AIH burden—as well as the lesser-known overlap syndrome. For more hepatology and gastroenterology coverage from ACG 2023, visit us at https://www.hcplive.com/conference/acg.
* Host Veeral Sheth, MD is joined by Megan Baldwin, PhD, CEO and Managing Director of Opthea Limited, to discuss OPT-302 or sozinibercept, the company's novel anti-VEGF-C / VEGF-D treatment for wet AMD and other retinal diseases. Please direct any podcast-related inquiries to firstname.lastname@example.org.
* Warren Jones, PhD, scientific founder of EarliTec Diagnostics and autism expert, discusses his team's development of an eye-tracking device recently authorized by the FDA and proven in clinical trials to predict autism consistent with expert diagnoses.
* After a historically low-transmission summer, new cases, hospitalizations and deaths due to COVID-19 have increased by approximately 18% in the US over the last week, according to CDC data. In a new interview, Donald J. Alcendor, PhD, associate professor, department of pathology microbiology and immunology, division of infectious diseases, Vanderbilt University Medical Center, and Editorial Advisory Board member, discussed the factors influencing the current iteration of COVID-19 in the US. Put briefly: “The virus is changing, and immunity is waning.” Want more COVID-19 and health care news updates? Visit us at HCPLive.com https://www.hcplive.com. Episode highlights: 0:16 Intro 1:36 The current climb in COVID-19: What’s happening? 3:58 Are the variants becoming harder to dodge? 7:01 How the end of the US public health emergency impacted prevention 11:07 Realistic vaccine expectations 13:13 Advancing COVID-19 antivirals 17:32 The future for mRNA vaccines infectious disease 21:27 Public health implications 22:58 A quiet COVID-19 summer: What went well? 25:06 Projecting future waves 28:26 Advice for clinicians in preparing patients
* In this episode, host Veeral Sheth, MD, and producer Connor Iapoce discuss 5 important presentations from ASRS 2023. The discussion centers around new data on geographic atrophy therapies, novel agents for DME, and the feasibility of home OCT. Please direct any podcast-related inquiries to email@example.com.
* The newest episode of New Insight with Veeral Sheth, MD features a conversation with David Eichenbaum, MD, the director of research for Retina Vitreous Associates of Florida. A seasoned clinical trial investigator and a friendly face at major medical meetings, Eichenbaum provides insights into his goals behind mentorship and inspiring others, sharing anecdotes about his own journey. On the heels of an already busy year, the experts discuss evolutions in the field and the pipeline, as the retina landscape changes each calendar month. In this vein, the two specialists discuss their ever-changing roles from investigators to mentors to stewards for the next generation of retina specialists. Please direct any podcast-related inquiries to show producer Connor Iapoce at firstname.lastname@example.org.
* In the latest episode of New Insight, Veeral Sheth, MD sat down with Cedric Francois, MD, PhD, co-founder and chief executive officer/president of Apellis Pharmaceuticals. The two experts discussed the company's landmark therapy, pegcetacoplan (SYFOVRE™), for geographic atrophy and the decades-long journey toward FDA approval. Sheth also asked about Francois' evolving role in the company and the interplay between being a scientist, clinician, and corporate executive. The experts also touched on how the GA treatment landscape might evolve over the next few years and what will shape the future of retina. Please direct any podcast-related inquiries to email@example.com.
* In this episode, Veeral Sheth, MD, sits down with Jay Duker, MD, the president and chief operating officer of Eyepoint Pharmaceuticals, for a discussion on his storied career in ophthalmology, the importance of fostering a relationship between clinicians and industry, and the current biotech Dr. Duker and team are working on at Eyepoint. Please direct any podcast-related inquiries to firstname.lastname@example.org.
* In this episode, Charles Wykoff, MD, PhD joins Dr. Sheth to provide insight into the recent landmark approval of pegcetacoplan injection (SYFOVRE™) for geographic atrophy, how clinical practice has changed as a result, and both the early struggles with and optimism for an ever-changing treatment landscape. Please direct any podcast-related inquiries to email@example.com.
* As part of our ARVO 2023 coverage, Dr. Sheth sat down with Pravin Dugel, MD, President of Iveric Bio. Together, the experts discussed the lead molecule for the company, avacincaptad pegol for geographic atrophy, and touched on the data being presented at the conference, as well as a look back at Dugel's career and his transition into industry.
* The inaugural episode of New Insight with Veeral Sheth, MD, our premier ophthalmology-focused podcast, features a conversation with Arshad Khanai, MD, the Director of Clinical Research at Sierra Eye Associates in Reno, Nevada. Together, our experts discuss their background and education in retina, and how they started working on clinical trials. They go on to describe the work that has led to recent landmark drug approvals in ophthalmology, including faricimab and pegcetacoplan, and the impact of these treatments on patients. Friends and colleagues for nearly 20 years, Sheth and Khanani talk a bit about their history, what mentorship means in medicine and their role as mentors to fellows and younger colleagues within the space. Lastly, the two KOLs discuss what they are looking forward to in the year, with particular mention of upcoming meetings and developments that may define the year 2023. We hope you enjoy our first episode! Keep an eye out for more from New Insight.
* The latest offering from Podcasts is , an in-depth series examining the biggest news in ophthalmology. The podcast will feature conversations on research news and new therapies, landmark findings from major medical meetings, and the day-to-day life of an ophthalmologist in the 21st century. A range of guests will join Dr. Sheth to share perspective and provide new insight into an ever-changing and ever-growing field. Stay tuned for our first episodes set to be released in April. But, for now, enjoy this first look at !
* As 2022 concludes, a dermatologist reflects on the first drug approved for vitiligo.
* Dr. Lally of New England Retina Consultants joins to discuss avacincaptad pegol, a promising injection treatment for GA, and its supporting data from the GATHER trial program. Will the complement C5 inhibitor drug receive FDA approval in 2023? Lally discusses this and more on the latest DocTalk.
* Ahead of the American College of Rheumatology 2022 Convergence meeting on Nov. 10-14, our editorial team sat down with planning committee member Zsuzsanna McMahan, MD, MHS, of Johns Hopkins University School of Medicine, to take a deep dive into the upcoming meeting.
* The FDA is expected to announce the final decision for the dual therapy AT-GAA, which uses miglustat in combination with cipaglucosidase alfa for treating Pompe disease, an inherited and often times fatal disorder. Expert Barry Byrne discusses the characteristics of the condition and what this FDA decision will mean for treatment.
* One of the most notable topics discussed at the 2022 American Academy of Ophthalmology Meeting in Chicago was new advancements in geographic atrophy (GA) treatment. A form of advanced age-related macular degeneration (AMD), there are no currently available treatments for the debilitating disease. In this episode of , we spoke with Arshad Khanani, MD, Director of Clinical Research, Sierra Eye Associates, on the findings from the GATHER2 trial on avacincaptad pegol for the treatment of GA. Throughout our conversation, Khanani laid out the first-time efficacy results of the phase 3 trial and its patient population, the overall safety of the agent, and what it might mean to alleviate the biggest unmet need in retina today. We hope you enjoy. If you are interested in more content from AAO 2022 or our ophthalmology coverage, visit us at HCPLive https://www.hcplive.com/.
* In the wake of Newborn Screening Awareness Month, this episode dives into a novel diagnostic precision medicine guidance tool called BeginNGS. Catherine Nester, RN, and Dr. Stephen Kingsmore, discuss the pivotal role of newborn screening in diagnosing rare diseases. As representatives from collaborating partners Inozyme Pharma and Rady Children's Institute that created this tool, they explain the impact that BeginNGS can have on the future of rare disease medicine.
* Martha Gulati, MD, Director of Preventive Cardiology, Associate Director of the Barbara Streisand Women’s Heart Center, Associate Director of Preventive and Cardiac Rehabilitation at Cedars-Sinai Medical Center, joins Heart Team to discuss current challenges in women’s cardiovascular disease research and clinical advancement. Gulati also provides guidance on improving female trial enrollment strategies and patient recruitment, and her thoughts on clinician perception of cardiovascular symptoms in men versus women. Heart Team is a monthly multimedia series hosted by Jorge Plutzky, MD, Director of Preventive Cardiology at Harvard Medical School, and Michael Farkouh, MD, Director of the Peter Munk Clinical Trials Unit and Vice Chair of Medicine at the University of Toronto. Watch the video of this interview, with more insights from Dr. Plutzky and Dr. Farkouh, at HCPLive.com. https://www.hcplive.com
* In the first episode from this new cardiovascular medicine series, hosts Dr. Jorge Plutzky and Dr. Michael Farkouh speak with University of Maryland's Dr. Matthew Weir about the growing involvement of renal care in modern heart disease patients.
* The second episode of the 2-part Rare Disease Report shifts to a clinical perspective with the expertise of Dr. Pestana, a pediatric epileptologist at the Epilepsy Center, Cleveland Clinic Neurological Institute who treats patients with CDKL5 deficiency disorder (CDD).
* In the first episode of a 2-part Rare Disease Report, Whitney Mitchell, mother and caregiver to her 6 year old daughter Havilah, shared her experience leading up to, and now living with, Havilah’s CDKL5 deficiency disorder (CDD) diagnosis.